Covaxx Initiates P-II Trial of UB-612 Against COVID-19 in Taiwan

Shots:

• The Taiwan Ministry of Health and Welfare granted conditional approval to initiate P-II trial of UB-612 in 3,850 subjects including adolescents, adults, and seniors across 11 medical centers and hospitals in Taiwan
• Additionally, Covaxx collaborated with UNMC to conduct clinical trials in the US, and with Dasa S.A. to conduct P-II/III study and distribute vaccines within Brazil. Covaxx also collaborated with Aurobindo to distribute the vaccine in India and UNICEF
• COVAXX is in production for the first 100M doses and subsequently over 500M doses in 2021

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: COVAXX